Olinvacimab

• Description :

  Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a Kd value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer[1].

• Product Name Alternative :

  TTAC-0001

• UNSPSC :

  12352203

• Target :

  VEGFR

• Type :

  Inhibitory Antibodies

• Related Pathways :

  Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/olinvacimab.html

• Purity :

  95.00

• Solubility :

  10 mM in DMSO

• Smiles :

  [Olinvacimab]

• Molecular Weight :

  (148.16 kDa)

• References & Citations :

  [1]Lee WS, et al. TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis. MAbs. 2015;7 (5) :957-68.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 2

• CAS Number :

  [2095504-49-5]